Status:
TERMINATED
Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Non-Small-Cell Lung
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel, carboplatin and bevacizumab as first-line treatment in patients with locally advanced or metastatic nonsqua...
Detailed Description
PF-3512676 dosing was stopped 21 June 2007 when Pfizer decided to stop the administration of PF-3512676 in all trials which combined PF-3512676 with cytotoxic chemotherapy. the decision was made subse...
Eligibility Criteria
Inclusion
- Advanced Stage IIIb with pleural effusion or Stage IV nonsquamous non-small cell lung cancer
- ECOG Performance Status 0-1
- Measurable disease per RECIST criteria
Exclusion
- Squamous cell, small cell, or carcinoid lung cancer
- CNS metastasis
- Pre-existing autoimmune or antibody mediated disease
- Prior systemic treatment for NSCLC with chemo, immunotherapy, biologics, or investigation drugs
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00313768
Start Date
December 1 2005
End Date
May 1 2008
Last Update
September 28 2009
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Bessemer, Alabama, United States, 35022
2
Pfizer Investigational Site
Birmingham, Alabama, United States, 32511
3
Pfizer Investigational Site
Birmingham, Alabama, United States, 35205
4
Pfizer Investigational Site
Birmingham, Alabama, United States, 35209